Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0EKVAD
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Alpha-CD22-LC-K149C-10
|
|||||
| Synonyms |
AlphaCD22-LC-K149C-10
Click to Show/Hide
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 1 Indication(s)
Diffuse large B-cell lymphoma [ICD11:2A81]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Antibody Name |
Anti-CD22-LC-K149C
|
Antibody Info | ||||
| Antigen Name |
B-cell receptor CD22 (CD22)
|
Antigen Info | ||||
| Payload Name |
seco-CBI-dimer
|
Payload Info | ||||
| Therapeutic Target |
Human Deoxyribonucleic acid (hDNA)
|
Target Info | ||||
| Linker Name |
Mc-peptidomimetic based linker 10
|
Linker Info | ||||
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 68.00% (Day 12) | Positive CD22 expression (CD22+++/++) | ||
| Method Description |
In vivo efficacy of TDCs aCD22-LC-K149C-10 and aLy6E-LC-K149C-10 in the WSU-DLCL2 xenograft model. single administrations of aCD22-LC-K149C-10 (0.3 mg/kg) to mice bearing CD22-expressing WSU-DLCL2 tumor xenografts model.
|
||||
| In Vivo Model | WSU-DLCL2 CDX model | ||||
| In Vitro Model | Diffuse large B-cell lymphoma | WSU-DLCL2 cells | CVCL_1902 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 87.00 (Day 12) | Positive CD22 expression (CD22+++/++) | ||
| Method Description |
In vivo efficacy of TDCs aCD22-LC-K149C-10 and aLy6E-LC-K149C-10 in the WSU-DLCL2 xenograft model. single administrations of aCD22-LC-K149C-10 (1 mg/kg) to mice bearing CD22-expressing WSU-DLCL2 tumor xenografts model.
|
||||
| In Vivo Model | WSU-DLCL2 CDX model | ||||
| In Vitro Model | Diffuse large B-cell lymphoma | WSU-DLCL2 cells | CVCL_1902 | ||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.04 nM | Positive CD22 expression (CD22+++/++) | ||
| Method Description |
Seco-CBI-Dimer TDCs Exhibit Potent Antigen-Dependent Antiproliferation Effects in Vitro. All cell-based assay results are reported as the arithmetic mean of at least three separate runs (n = 3).
|
||||
| In Vitro Model | Diffuse large B-cell lymphoma | WSU-DLCL2 cells | CVCL_1902 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.07 nM | Positive CD22 expression (CD22+++/++) | ||
| Method Description |
Seco-CBI-Dimer TDCs Exhibit Potent Antigen-Dependent Antiproliferation Effects in Vitro. All cell-based assay results are reported as the arithmetic mean of at least three separate runs (n = 3).
|
||||
| In Vitro Model | Burkitt lymphoma | BJAB cells | CVCL_5711 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | > 130 nM | Positive CD22 expression (CD22+++/++) | ||
| Method Description |
Seco-CBI-Dimer TDCs Exhibit Potent Antigen-Dependent Antiproliferation Effects in Vitro. All cell-based assay results are reported as the arithmetic mean of at least three separate runs (n = 3).
|
||||
| In Vitro Model | T acute lymphoblastic leukemia | Jurkat cells | CVCL_0065 | ||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.